Are peptides FDA approved?

A few are. Semaglutide, tirzepatide, sermorelin, tesamorelin and bremelanotide hold FDA approvals for defined indications. The majority of peptides discussed in longevity medicine hold no approval for any use as of October 2026.

What does peptide therapy evidence actually show?

It varies by substance, which is why every entry in this library carries an evidence grade from A to D. Grade A means an approved drug with randomised controlled trials; grade D means no published clinical data at all.

Is BPC-157 legal in the United States?

BPC-157 is not FDA-approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound, against the advice of FDA's own scientists. FDA has not decided, so as of October 22, 2026 it still cannot be compounded under section 503A.

Peptide Library — Evidence and FDA Status of 19 Peptides (2026)

§ — The peptide library

Peptides, as researched — not as sold.

This library records what nineteen peptides are being researched for, what the evidence shows, and where the FDA stands — each with the date of our last verification. It reports research and regulation; it recommends nothing and sells nothing.

§ — The peptide finder

Peptide Finder

Five questions about your goal — then the peptides being researched for it, with evidence grade and FDA status, dated October 2026.

19 peptides · 9 research goals

Start the peptide finder →Regulatory status tracker →

Approved drug with randomized controlled trials for the approved indication

Human clinical data exists, but no approval for the researched use

Animal or in-vitro data only, no controlled human trials

No published clinical data; use rests on anecdote

Reviewed October 2026 · Sources: FDA, EMA

This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.

01 — Browse by goal

Nine research goals, nine honest answers.

02 — A–Z library

Nineteen substance profiles, status first.

03 — Regulatory status tracker

What changed, and when.

The FDA's compounding position on peptides moved three times in 2026 and an interim policy is under White House review. The tracker records each entry with the date of our last verification — currently October 2026.

Open the tracker →Machine-readable status.json →

5 of 19 peptides in this library hold an FDA approval for a defined indication.

04 — Frequently asked

Questions people actually search for.

Are peptides FDA approved?: A few are. Semaglutide, tirzepatide, sermorelin, tesamorelin and bremelanotide hold FDA approvals for defined indications. The majority of peptides discussed in longevity medicine hold no approval for any use as of October 2026.
What does peptide therapy evidence actually show?: It varies by substance, which is why every entry in this library carries an evidence grade from A to D. Grade A means an approved drug with randomised controlled trials; grade D means no published clinical data at all.
Is BPC-157 legal in the United States?: BPC-157 is not FDA-approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound, against the advice of FDA's own scientists. FDA has not decided, so as of October 22, 2026 it still cannot be compounded under section 503A.

Goal pages carry their own questions — start with tissue repair.

Reviewed October 2026 · Sources: FDA, EMA